RAPT Therapeutics

Yahoo Finance • 2 months ago

RAPT Therapeutics, Inc. (RAPT): Worst 52-Week Low Stock to Buy Now

We recently compiled a list of the 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers.In this article, we are going to take a look at where RAPT Therapeutics, Inc. (NASDAQ:RAPT) stands against the other Worst 52-Week Low Sto... Full story

Yahoo Finance • 2 months ago

RAPT Therapeutics, Inc. (RAPT) Stock Falls Following FDA Setback; Short Sellers Cite Unprofitability

We recently published a list of 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers. In this article, we are going to take a look at where RAPT Therapeutics, Inc. (NASDAQ:RAPT) stands against the other worst 52-week low stock... Full story

Yahoo Finance • last year

RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy

Positive clinical and molecular effects observed, with improvements demonstrated in key exploratory efficacy endpoints - percent change in EASI, EASI-50, vIGA and pruritis NRS - at fourweeksFurther deepening of response in percent change i... Full story

Yahoo Finance • last year

RAPT Therapeutics Reports Third Quarter 2023 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule the... Full story

Yahoo Finance • last year

RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC

- Confirmed objective response rate (ORR) of 40% in PD-L1 positive (TPS ≥1%)patients with no prior checkpoint inhibitor therapy (CPI) - Median progression-free survival (PFS) of 6.3 months in PD-L1 positive patients at time of data cut of... Full story

Yahoo Finance • last year

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule the... Full story

Yahoo Finance • last year

RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule the... Full story

Yahoo Finance • last year

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule the... Full story

Yahoo Finance • 2 years ago

RAPT Therapeutics Reports First Quarter 2023 Financial Results

SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule ther... Full story

Yahoo Finance • 2 years ago

RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel

SOUTH SAN FRANCISCO, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule ther... Full story

Yahoo Finance • 2 years ago

RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma

SOUTH SAN FRANCISCO, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule th... Full story

Yahoo Finance • 2 years ago

RAPT Therapeutics, Inc.: Company Investigated by the Portnoy Law Firm

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 26, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises RAPT Therapeutics, Inc. (“RAPT Therapeutics,” or the “Company”) (NASD... Full story

Yahoo Finance • 2 years ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RAPT Therapeutics, Inc. - RAPT

NEW YORK, March 20, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  RAPT Therapeutics, Inc. (“RAPT” or the “Company”) (NASDAQ: RAPT). Such investors are advised to contact Robert S. Willoughby at... Full story

Yahoo Finance • 2 years ago

Investigation of RAPT Therapeutics, Inc. (RAPT) Announced by Holzer & Holzer, LLC

ATLANTA, March 20, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether RAPT Therapeutics, Inc. (“RAPT Therapeutics,” or the “Company”) (NASDAQ: RAPT) complied with federal securities laws. On March 14, 2023, the Compan... Full story

Yahoo Finance • 2 years ago

RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results

SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule th... Full story

Yahoo Finance • 2 years ago

RAPT Therapeutics to Participate in the SVB Securities Global Biopharma Conference

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecul... Full story

Yahoo Finance • 2 years ago

RAPT Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecul... Full story

Yahoo Finance • 2 years ago

RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer

SOUTH SAN FRANCISCO, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecul... Full story

Yahoo Finance • 2 years ago

RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress

SOUTH SAN FRANCISCO, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commerci... Full story

Yahoo Finance • 2 years ago

RAPT Therapeutics Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commerci... Full story